Strickler, J. H., Camidge, D. R., Kuboki, Y., Yamamoto, N., Sommerhalder, D., Vasilopoulos, A., … Bar, J. (2023). 691P Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors. In Annals of Oncology (Vol. 34, pp. S482–S482). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.1877

Strickler, J. H., D. R. Camidge, Y. Kuboki, N. Yamamoto, D. Sommerhalder, A. Vasilopoulos, R. R. Li, et al. “691P Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors.” In Annals of Oncology, 34:S482–S482. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.1877.

Strickler JH, Camidge DR, Kuboki Y, Yamamoto N, Sommerhalder D, Vasilopoulos A, et al. 691P Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors. In: Annals of Oncology. Elsevier BV; 2023. p. S482–S482.

Strickler, J. H., et al. “691P Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors.” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S482–S482. Crossref, doi:10.1016/j.annonc.2023.09.1877.

Strickler JH, Camidge DR, Kuboki Y, Yamamoto N, Sommerhalder D, Vasilopoulos A, Li RR, Freise K, Morrison-Thiele G, Neagu Aristide MR, Bar J. 691P Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors. Annals of Oncology. Elsevier BV; 2023. p. S482–S482.